A Single Arm, Multicenter, Phase II Study of BEZ235 as Monotherapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) After Failure of Platinum Based Chemotherapy.

Trial Profile

A Single Arm, Multicenter, Phase II Study of BEZ235 as Monotherapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) After Failure of Platinum Based Chemotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Dactolisib (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jan 2016 Results published in the BJU International
    • 02 Jun 2015 Primary endpoint (Progression-free survival rate) has not been met, according to 2015 ASCO abstract.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top